Efficacy and Safety of Nemtabrutinib in Participants With Hematologic Malignancies

Trial purpose

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM).

View full trial information on Clinicaltrials.gov

	national trial reference number	NCT04728893
	Conditions	Chronic Lymphocytic Leukemia, Hematologic Malignancies, Non-Hodgkins Lymphoma, Waldenstroms Macroglobulinemia
	Age Range	18+
	Sex	All
	Current trial phase	2
	Trial start and end dates	04-05-2021 03-19-2027

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT04728893

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.